Eden Research (LON:EDEN) Shares Up 14.9% – Should You Buy?

Eden Research plc (LON:EDEN)’s stock price traded up 14.9% during trading on Thursday . The stock traded as high as GBX 4.60 ($0.06) and last traded at GBX 3.85 ($0.05). 2,232,832 shares changed hands during trading, an increase of 225% from the average session volume of 687,915 shares. The stock had previously closed at GBX 3.35 ($0.04).

Eden Research Trading Up 1.3%

The company has a market capitalization of £21.33 million, a PE ratio of -14.01 and a beta of 0.92. The company has a 50 day simple moving average of GBX 2.81 and a 200 day simple moving average of GBX 3.43. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.42 and a current ratio of 3.80.

Eden Research (LON:EDEN) last announced its earnings results on Tuesday, May 6th. The company reported GBX (0.36) ($0.00) earnings per share (EPS) for the quarter. Eden Research had a negative net margin of 38.70% and a negative return on equity of 11.63%. Analysts anticipate that Eden Research plc will post -66.0000038 earnings per share for the current year.

Insider Activity at Eden Research

In related news, insider Alexander John Abrey acquired 167,947 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The stock was purchased at an average cost of GBX 3 ($0.04) per share, for a total transaction of £5,038.41 ($6,684.01). Also, insider Sean M. Smith acquired 426,986 shares of the business’s stock in a transaction that occurred on Tuesday, April 1st. The shares were bought at an average price of GBX 234 ($3.10) per share, with a total value of £999,147.24 ($1,325,480.55). 14.02% of the stock is currently owned by corporate insiders.

Eden Research Company Profile

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

Eden’s products are formulated with terpene active ingredients, based on natural plant defence metabolites.